Elsevier

The Lancet

Volume 357, Issue 9271, 9 June 2001, Pages 1850-1851
The Lancet

Research Letters
Anti-epiligrin cicatricial pemphigoid and relative risk for cancer

https://doi.org/10.1016/S0140-6736(00)04971-0Get rights and content

Summary

It is not known whether patients with anti-epiligrin cicatricial pemphigoid (AECP) have an increased risk of malignancy. We calculated the expected numbers of cancers in a c hort of 35 such patients based on respective incidence rates for all cancers in the National Cancer Institute's Surveillance, Epidemiology, and End Results (NCI SEER) Registry. Ten patients in this cohort had solitary solid cancers; eight patients developed cancer after onset of AECP (seven within 14 months). The relative risk (RR) for cancer in this cohort was 6·8 (95% confidence intervals [CI]: 3·3-12·5). AECP seems to be associated with an increased relative risk for cancer.

References (5)

There are more references available in the full text version of this article.

Cited by (0)

View full text